Completed PHASE2 INTERVENTIONAL 2-arm NCT00090610

Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer

Multicenter, Randomized, Phase II Comparative Study to Compare Efficacy & Safety of Taxotere®/Carboplatin Combination Therapy vs Sequential Therapy w/ Taxotere® Then Carboplatin as Second-line Treatment of Patients w/ Relapsed, Platinum-sensitive Ovarian Cancer

Sponsor: Aventis Pharmaceuticals

Conditions Ovarian Cancer

Interventions Carboplatin Docetaxel

Updated 6 times since 2017 Last updated: Feb 5, 2015 Started: Oct 31, 2003 Primary completion: Mar 31, 2009 Completion: Oct 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Ovarian Cancer, this trial is completed. The trial is conducted by Aventis Pharmaceuticals and has accumulated 6 data snapshots since 2003. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Oct 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aventis Pharmaceuticals
Duke University

Data source: Duke University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Asheville, United States , Austin, United States , Baltimore, United States , Bettendorf, United States , Chapel Hill, United States , Charleston, United States , Charlotte, United States , Durham, United States , Fort Myers, United States , Hackensack, United States and 9 more locations